Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Heal... Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19). Mehr anzeigen
Soligenix Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma PR Newswire PRINCETON, N.J., Nov. 19, 2024 Phase 3 clinical study of HyBryte™ in CTCL initiating in...
Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the treatment of Behçet's Disease PR Newswire PRINCETON, N.J., Nov. 14, 2024 Study DUS-AUBD-01 opens patient...
Soligenix Announces Recent Accomplishments And Third Quarter 2024 Financial Results PR Newswire PRINCETON, N.J., Nov. 8, 2024 PRINCETON, N.J., Nov. 8, 2024 /PRNewswire/ -- Soligenix, Inc...
PRINCETON, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Soligenix, Inc. (Nasdaq: SNGX) (“Soligenix” or the “Company”) a late-stage biopharmaceutical company focused on developing and commercializing...
Soligenix Receives Hong Kong Patent for Improved Production of Synthetic Hypericin PR Newswire PRINCETON, N.J., Oct. 22, 2024 Active Ingredient in HyBryte™ for the Treatment of Cutaneous T-Cell...
Soligenix Invited to Present at Upcoming Investor Conferences PR Newswire PRINCETON, N.J., Oct. 16, 2024 PRINCETON, N.J., Oct. 16, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.22 | -6.11111111111 | 3.6 | 3.71 | 3.3755 | 16906 | 3.5540318 | CS |
| 4 | -0.21 | -5.8495821727 | 3.59 | 3.99 | 3.3755 | 41317 | 3.67040331 | CS |
| 12 | -0.09 | -2.59365994236 | 3.47 | 4.87 | 3.27 | 122663 | 4.17321512 | CS |
| 26 | -2.7512 | -44.8721294363 | 6.1312 | 14.8299 | 1.8301 | 1372416 | 7.11625453 | CS |
| 52 | -3.34 | -49.7023809524 | 6.72 | 32 | 1.8301 | 2109374 | 9.87244784 | CS |
| 156 | -203.02 | -98.3624031008 | 206.4 | 240 | 1.8301 | 891498 | 28.13973989 | CS |
| 260 | -222.532 | -98.503842204 | 225.912 | 883.2 | 1.8301 | 1073363 | 214.92207626 | CS |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
